BioNTech is rated Hold due to a shrinking drug pipeline, ongoing negative cash flow, and dependence on two main products: pumitamig and gotistobart. Although the company reported a Q3 profit, the gap between reported earnings and actual cash flow is widening, with liquid assets decreasing despite revenue from partnerships. The revised revenue outlook shows only modest improvement, and risks remain high due to cash burn and portfolio concentration. Future rating changes depend on clinical outcomes and cash flow management.
BioNTech SE trades with a market cap of $21.83 billion and an enterprise value of $5.65 billion on Pluang as of Nov 04, 2026 21:41 WIB. The stock price is currently USD 88.76, showing a 1-day gain of 2.12%. Trading volume stands at 1,151,374 shares, with a typical hold time of 61 days on the platform, reflecting steady investor interest despite the company's challenges.
